---
title: "LENZ Therapeutics, Inc. (LENZ.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/LENZ.US.md"
symbol: "LENZ.US"
name: "LENZ Therapeutics, Inc."
industry: "制藥"
---

# LENZ Therapeutics, Inc. (LENZ.US)

| Item | Detail |
|------|--------|
| Industry | 制藥 |
| Location | 美股市場 |
| Website | [www.lenz-tx.com](https://www.lenz-tx.com) |

## Company Profile

LENZ Therapeutics, Inc. 是一家生物制藥公司，專注于在美國開發和商業化改善視力的療法。其產品候選藥物包括 LNZ100 和 LNZ101，目前正在進行治療老花眼的第三階段臨床試驗。LENZ Therapeutics, Inc

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-26T04:30:15.000Z

**Overall: C (0.58)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 77 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 3.17% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 2.13 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 413.65M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 17.50M |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -28.78% | E |
| Profit Margin | -336.47% | E |
| Gross Margin | 100.00% | A |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% | D |
| Net Profit YoY | 3.17% | C |
| Total Assets YoY | -5.94% | D |
| Net Assets YoY | -9.92% | D |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -29.72% | D |
| OCF YoY | 0.00% | D |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.08 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 7.96% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - LENZ Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-28.78%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-336.47%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "3.17%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-5.94%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-9.92%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-29.72%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.08",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "7.96%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 禮來 (US.LLY) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 03 | 羅氏(ADR) (US.RHHBY) | A | B | B | D | C | B |
| 04 | 阿斯利康 (US.AZN) | A | B | C | D | C | B |
| 05 | 諾華制藥 (US.NVS) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -7.03 | 166/257 | - | - | - |
| PB | 2.13 | 92/257 | 5.09 | 4.13 | 2.88 |
| PS (TTM) | 23.64 | 125/257 | 226.35 | 53.43 | 29.68 |
| Dividend Yield | 0.00% | - | 4.72% | 4.48% | 4.05% |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-20T05:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 6 | 86% |
| Overweight | 1 | 14% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 30.03 |
| Highest Target | 60.00 |
| Lowest Target | 36.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/LENZ.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/LENZ.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/LENZ.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.